FCE 28260
FCE 28260 is a 5-alpha-reductase inhibitor drug with antiandrogenic activity, which was developed for the treatment of benign prostatic hyperplasia and androgenic (or androgenetic) alopecia in the 1990s. Its current status is unknown.
In a 1996 study, FCE 28260 inhibited rat and human 5-alpha-reductase with half maximal inhibitory concentrations (IC50) of 15 and 16 nM, respectively, while finasteride had values of 30 and 52 nM.
References
1 2 Giudici, D.; Briatico, G.; Cominato, C.; Zaccheo, T.; Iehlè, C.; Nesi, M.; Panzeri, A.; Di Salle, E. (1996). "FCE 28260, a new 5 alpha-reductase inhibitor: In vitro and in vivo effects". The Journal of Steroid Biochemistry and Molecular Biology 58 (3): 299–305. doi:10.1016/0960-0760(96)00040-4. PMID 8836165.
↑ EP 0782582, Salle Enrico Di, Marcella Nesi, Achille Panzeri, "Epimers of (22RS)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide", published 1997-07-09 .
